Publications

  1. Tsang M, Hampel PJ, Rabe KG, Brieghel C, Ding W, Leis JF, Hilal T, Kenderian SS, Wang Y, Muchtar E, Koehler AB, Van Dyke DL, Hanson CA, Shi M, Slager SL, Kay NE, Hjalgrim H, Niemann CU, Parikh SA, Rotbain EC. Comparison of Frontline Therapies in Older Adults Age >/= 80 Years With Chronic Lymphocytic Leukemia (CLL): A Mayo Clinic and Danish Nation-Wide Study. Am J Hematol 2025 Sep; 100 (9):1678-1681 Epub 2025 June 18
    View PubMed
  2. Tsang M, Hampel PJ, Rabe KG, Brieghel C, Ding W, Leis JF, Hilal T, Kenderian SS, Wang Y, Muchtar E, Koehler AB, Van Dyke DL, Hanson CA, Shi M, Slager SL, Kay NE, Hjalgrim H, Niemann CU, Parikh SA, Rotbain EC. Comparison of Frontline Therapies in Older Adults Age >/= 80 Years With Chronic Lymphocytic Leukemia (CLL): A Mayo Clinic and Danish Nation-Wide Study. Am J Hematol 2025 Sep; 100 (9):1678-1681 Epub 2025 June 18
    View PubMed
  3. Miller CR, Huang Y, Allan JN, Bhat SA, Bond D, Brander D, Byrd JC, Chavez J, Chong E, Danilov A, Dowling MR, Dvorak-Kornaus K, Hampel PJ, Ho C, Islam P, Malakhov N, Matasar M, Miller S, Parikh SA, Rabe KG, Rhodes JM, Roeker LE, Rogers KA, Saha A, Skarbnik A, Scott H, Schade J, Shadman M, Shouse G, Sojitra P, Stephens DM, Thompson MC, Thompson PA, Wang Y, Woyach JA, Yano M, Omer Z, Kittai AS. Prognostic Implication of Karyotypic Evaluation in Patients With Richter Transformation in the Modern Era. Am J Hematol. 2025 Sep; 100(9):1709-1713. Epub 2025 Jul 02.
    View PubMed
  4. Kittai AS, Marchetti M, Al-Sawaf O, Benjamini O, Danilov AV, Davids MS, Eichhorst B, Eyre TA, Frustaci AM, Hallek M, Hampel PJ, Herishanu Y, Hicks RJ, Kater AP, King RL, Martin-Subero JI, Owen C, Parry E, Ponzoni M, Rossi D, Siddiqi T, Stilgenbauer S, Tam CS, Hacken ET, Thompson PA, Wierda W, Gaidano G, Woyach JA, Ghia P. International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations. Blood 2025 Jul 17; 146 (3):291-303
    View PubMed
  5. Kittai AS, Marchetti M, Al-Sawaf O, Benjamini O, Danilov AV, Davids MS, Eichhorst B, Eyre TA, Frustaci AM, Hallek M, Hampel PJ, Herishanu Y, Hicks RJ, Kater AP, King RL, Martin-Subero JI, Owen C, Parry E, Ponzoni M, Rossi D, Siddiqi T, Stilgenbauer S, Tam CS, Hacken ET, Thompson PA, Wierda W, Gaidano G, Woyach JA, Ghia P. International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations. Blood 2025 Jul 17; 146 (3):291-303
    View PubMed
  6. Kosydar S, Archibald WJ, Hampel PJ, Call TG, Achenbach SJ, Rabe KG, Hanson CA, Koehler AB, Muchtar E, Kenderian SS, Leis JF, Wang Y, Roeker LE, Hilal T, Tsang M, Parrondo RD, Braggio E, Shi M, Schwager SM, Slager SL, Kay NE, Parikh SA. The role of imaging studies in predicting time to first treatment and overall survival in high-count monoclonal B-cell lymphocytosis. Br J Haematol. 2025 Jul 15 Epub 2025 July 15
    View PubMed
  7. Kosydar S, Archibald WJ, Hampel PJ, Call TG, Achenbach SJ, Rabe KG, Hanson CA, Koehler AB, Muchtar E, Kenderian SS, Leis JF, Wang Y, Roeker LE, Hilal T, Tsang M, Parrondo RD, Braggio E, Shi M, Schwager SM, Slager SL, Kay NE, Parikh SA. The role of imaging studies in predicting time to first treatment and overall survival in high-count monoclonal B-cell lymphocytosis. Br J Haematol. 2025 Jul 15 Epub 2025 July 15
    View PubMed
  8. Gile JJ, Mondello P, Wang Z, Li Y, Bansal R, Gandhi S, Zhang H, Babadi E, Martinez K, McCoy G, Shao Z, Regan K, Hathcock MA, Wang P, Wang J, Al Saleh AS, Ruan G, Ansell SM, Bennani NN, Johnston PB, Paludo J, Villasboas-Bisneto JC, Khurana A, Durani U, Wang Y, Hampel PJ, Rosenthal A, Munoz J, Moreno E, Castro JE, Murthy HS, Kharfan-Dabaja M, Kenderian SS, Kim JJ, Shen R, Mattie M, Lin Y, Witzig TE. Hypomagnesemia in lymphoma patients receiving CAR T therapy correlates with immune dysfunction and decreased survival. Exp Hematol Oncol. 2025 Apr 30; 14 (1):63
    View PubMed
  9. Gile JJ, Mondello P, Wang Z, Li Y, Bansal R, Gandhi S, Zhang H, Babadi E, Martinez K, McCoy G, Shao Z, Regan K, Hathcock MA, Wang P, Wang J, Al Saleh AS, Ruan G, Ansell SM, Bennani NN, Johnston PB, Paludo J, Villasboas-Bisneto JC, Khurana A, Durani U, Wang Y, Hampel PJ, Rosenthal A, Munoz J, Moreno E, Castro JE, Murthy HS, Kharfan-Dabaja M, Kenderian SS, Kim JJ, Shen R, Mattie M, Lin Y, Witzig TE. Hypomagnesemia in lymphoma patients receiving CAR T therapy correlates with immune dysfunction and decreased survival. Exp Hematol Oncol. 2025 Apr 30; 14 (1):63
    View PubMed
  10. Bailen RJ, Aasum MI, Tamminga LM, Koehler AB, Behnken AL, Harden J, Hampel PJ, Wang Y, Muchtar E, Kenderian SS, Kay NE, Rabe KG, Ding W, Call TG, Parikh SA. A pilot study to determine the feasibility and safety of pharmacist and nurse driven management of venetoclax ramp-up in patients with chronic lymphocytic leukemia. J Oncol Pharm Pract. 2025 Apr 1; 10781552251323195 Epub 2025 Apr 01
    View PubMed
  11. Bailen RJ, Aasum MI, Tamminga LM, Koehler AB, Behnken AL, Harden J, Hampel PJ, Wang Y, Muchtar E, Kenderian SS, Kay NE, Rabe KG, Ding W, Call TG, Parikh SA. A pilot study to determine the feasibility and safety of pharmacist and nurse driven management of venetoclax ramp-up in patients with chronic lymphocytic leukemia. J Oncol Pharm Pract. 2025 Apr 1; 10781552251323195 Epub 2025 Apr 01
    View PubMed
  12. Kittai AS, Huang Y, Miller S, Allan JN, Bhat SA, Bond DA, Brander DM, Byrd JC, Chavez JC, Chong E, Davids MS, Danilov AV, Ding W, Dowling MR, Dvorak-Kornaus K, Freedman H, Hampel PJ, Ho C, Hwang SR, Islam P, Malakhov N, Matasar M, Miller C, Omer Z, Parikh SA, Parry E, Rabe KG, Raess PW, Rai M, Roeker L, Rhodes J, Rogers KA, Saha A, Schade J, Scott HW, Shadman M, Shouse G, Skarbnik A, Spurgeon S, Stephens DM, Thompson MC, Thompson PA, Wang Y, Yano M, Woyach JA. Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL. Blood Cancer J 2025 Feb 20; 15 (1):23
    View PubMed
  13. Kittai AS, Huang Y, Miller S, Allan JN, Bhat SA, Bond DA, Brander DM, Byrd JC, Chavez JC, Chong E, Davids MS, Danilov AV, Ding W, Dowling MR, Dvorak-Kornaus K, Freedman H, Hampel PJ, Ho C, Hwang SR, Islam P, Malakhov N, Matasar M, Miller C, Omer Z, Parikh SA, Parry E, Rabe KG, Raess PW, Rai M, Roeker L, Rhodes J, Rogers KA, Saha A, Schade J, Scott HW, Shadman M, Shouse G, Skarbnik A, Spurgeon S, Stephens DM, Thompson MC, Thompson PA, Wang Y, Yano M, Woyach JA. Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL. Blood Cancer J 2025 Feb 20; 15 (1):23
    View PubMed
  14. Hampel PJ, Rabe KG, Wang Y, Hwang SR, Kenderian SS, Muchtar E, Leis JF, Koehler AB, Tsang M, Hilal T, Parrondo R, Bailen RJ, Schwager SM, Hanson CA, Braggio E, Slager SL, Shi M, Zepeda-Mendoza CJ, Van Dyke DL, Shanafelt TD, King RL, Call TG, Kay NE, Ding W, Parikh SA. Incidence of Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma in the targeted therapy era. Leukemia. 2025 Feb; 39 (2):503-507 Epub 2024 Dec 10
    View PubMed
  15. Hampel PJ, Rabe KG, Wang Y, Hwang SR, Kenderian SS, Muchtar E, Leis JF, Koehler AB, Tsang M, Hilal T, Parrondo R, Bailen RJ, Schwager SM, Hanson CA, Braggio E, Slager SL, Shi M, Zepeda-Mendoza CJ, Van Dyke DL, Shanafelt TD, King RL, Call TG, Kay NE, Ding W, Parikh SA. Incidence of Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma in the targeted therapy era. Leukemia. 2025 Feb; 39 (2):503-507 Epub 2024 Dec 10
    View PubMed
  16. Koehler AB, Rabe KG, Crusan DJ, Call TG, Achenbach SJ, Hampel PJ, Kenderian SS, Leis JF, Wang Y, Muchtar E, Tsang M, Hilal T, Parrondo R, Bailey KR, Ding W, Bailen R, Schwager SM, Shi M, Hanson CA, Slager SL, Kay NE, Ashrani AA, Parikh SA. Incidence, risk factors, and outcomes of patients with monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia who develop venous thromboembolism. J Thromb Haemost. 2025 Jan; 23 (1):149-157 Epub 2024 Sept 27
    View PubMed
  17. Koehler AB, Rabe KG, Crusan DJ, Call TG, Achenbach SJ, Hampel PJ, Kenderian SS, Leis JF, Wang Y, Muchtar E, Tsang M, Hilal T, Parrondo R, Bailey KR, Ding W, Bailen R, Schwager SM, Shi M, Hanson CA, Slager SL, Kay NE, Ashrani AA, Parikh SA. Incidence, risk factors, and outcomes of patients with monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia who develop venous thromboembolism. J Thromb Haemost. 2025 Jan; 23 (1):149-157 Epub 2024 Sept 27
    View PubMed
  18. Sekar A, Griffin R, Parikh SA, Genovese G, Robinson DP, Norman AD, Olson JE, Rabe KG, Hoel MS, Boddicker NJ, Hampel PJ, Kay NE, Cerhan JR, Braggio E, Hanson CA, Vachon CM, Shanafelt TD, Ebert BL, Slager SL. Mosaic chromosomal alterations (mCAs) in individuals with monoclonal B-cell lymphocytosis (MBL). Blood Cancer J. 2024 Nov 6; 14 (1):193 Epub 2024 Nov 06
    View PubMed
  19. Sekar A, Griffin R, Parikh SA, Genovese G, Robinson DP, Norman AD, Olson JE, Rabe KG, Hoel MS, Boddicker NJ, Hampel PJ, Kay NE, Cerhan JR, Braggio E, Hanson CA, Vachon CM, Shanafelt TD, Ebert BL, Slager SL. Mosaic chromosomal alterations (mCAs) in individuals with monoclonal B-cell lymphocytosis (MBL). Blood Cancer J. 2024 Nov 6; 14 (1):193 Epub 2024 Nov 06
    View PubMed
  20. Glimelius I, Kleinstern G, Robinson DP, Mansouri L, Rostgaard K, Hjalgrim H, Niemann CU, Mattsson M, Rabe KG, Hampel PJ, Parikh SA, Rosenquist R, Cerhan JR, Slager SL, Smedby KE. Medical history and lifestyle factors have limited impact on time-to-first-treatment in patients with chronic lymphocytic leukemia. EJHaem. 2024 Oct; 5 (5):998-1004 Epub 2024 Aug 27
    View PubMed
  21. Glimelius I, Kleinstern G, Robinson DP, Mansouri L, Rostgaard K, Hjalgrim H, Niemann CU, Mattsson M, Rabe KG, Hampel PJ, Parikh SA, Rosenquist R, Cerhan JR, Slager SL, Smedby KE. Medical history and lifestyle factors have limited impact on time-to-first-treatment in patients with chronic lymphocytic leukemia. EJHaem. 2024 Oct; 5 (5):998-1004 Epub 2024 Aug 27
    View PubMed
  22. Truong HL, Barreto JN, Mara KC, Hampel PJ, Micallef IN, Nowakowski GS, Thanarajasingam G, Thompson CA, Wang Y, Witzig TE, Herrmann SM, Leung N. Rechallenge With High-Dose Methotrexate After Treatment With Glucarpidase in Adult Patients With Lymphoma. JCO Oncol Pract. 2024 Jun; 20 (6):797-807 Epub 2024 Feb 26
    View PubMed
  23. Truong HL, Barreto JN, Mara KC, Hampel PJ, Micallef IN, Nowakowski GS, Thanarajasingam G, Thompson CA, Wang Y, Witzig TE, Herrmann SM, Leung N. Rechallenge With High-Dose Methotrexate After Treatment With Glucarpidase in Adult Patients With Lymphoma. JCO Oncol Pract. 2024 Jun; 20 (6):797-807 Epub 2024 Feb 26
    View PubMed
  24. Hampel PJ, Swaminathan M, Rogers KA, Parry EM, Burger JA, Davids MS, Ding W, Ferrajoli A, Hyak JM, Jain N, Kenderian SS, Wang Y, Wierda WG, Woyach JA, Parikh SA, Thompson PA. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia. Blood Adv. 2024 May 28; 8 (10):2342-2350
    View PubMed
  25. Hampel PJ, Swaminathan M, Rogers KA, Parry EM, Burger JA, Davids MS, Ding W, Ferrajoli A, Hyak JM, Jain N, Kenderian SS, Wang Y, Wierda WG, Woyach JA, Parikh SA, Thompson PA. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia. Blood Adv. 2024 May 28; 8 (10):2342-2350
    View PubMed
  26. Abdelbaky SB, Giacopelli B, Rabe KG, Yamaguchi K, Wu YZ, Yan H, Shanafelt TD, Parikh SA, Ding W, Hampel PJ, Brown S, Cerhan JR, Vachon CM, Kay NE, Hanson CA, Parker AS, Braggio E, Slager SL, Oakes CC. Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature. Blood. 2024 Apr 25; 143 (17):1752-1757
    View PubMed
  27. Abdelbaky SB, Giacopelli B, Rabe KG, Yamaguchi K, Wu YZ, Yan H, Shanafelt TD, Parikh SA, Ding W, Hampel PJ, Brown S, Cerhan JR, Vachon CM, Kay NE, Hanson CA, Parker AS, Braggio E, Slager SL, Oakes CC. Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature. Blood. 2024 Apr 25; 143 (17):1752-1757
    View PubMed
  28. Christopoulos G, Attia ZI, Achenbach SJ, Rabe KG, Call TG, Ding W, Leis JF, Muchtar E, Kenderian SS, Wang Y, Hampel PJ, Koehler AB, Kay NE, Kapoor P, Slager SL, Shanafelt TD, Noseworthy PA, Friedman PA, Herrmann J, Parikh SA. Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation in Patients With Chronic Lymphocytic Leukemia. JACC CardioOncol. 2024 Apr; 6 (2):251-263 Epub 2024 Apr 16
    View PubMed
  29. Christopoulos G, Attia ZI, Achenbach SJ, Rabe KG, Call TG, Ding W, Leis JF, Muchtar E, Kenderian SS, Wang Y, Hampel PJ, Koehler AB, Kay NE, Kapoor P, Slager SL, Shanafelt TD, Noseworthy PA, Friedman PA, Herrmann J, Parikh SA. Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation in Patients With Chronic Lymphocytic Leukemia. JACC CardioOncol. 2024 Apr; 6 (2):251-263 Epub 2024 Apr 16
    View PubMed
  30. Kosydar SR, Parikh SA, Lester SC, Rabe KG, Ding W, Burlile JF, Kenderian SS, Wang Y, Muchtar E, Koehler AB, Schwager SM, Slager SL, Kay NE, Call TG, Breen WG, Hampel PJ. Safety of radiotherapy for second primary malignancies in patients with chronic lymphocytic leukemia receiving concurrent novel agent treatment. Am J Hematol 2023 Nov; 98 (11):E318-E321 Epub 2023 Aug 24
    View PubMed
  31. Kosydar SR, Parikh SA, Lester SC, Rabe KG, Ding W, Burlile JF, Kenderian SS, Wang Y, Muchtar E, Koehler AB, Schwager SM, Slager SL, Kay NE, Call TG, Breen WG, Hampel PJ. Safety of radiotherapy for second primary malignancies in patients with chronic lymphocytic leukemia receiving concurrent novel agent treatment. Am J Hematol 2023 Nov; 98 (11):E318-E321 Epub 2023 Aug 24
    View PubMed
  32. Cass SH, Tobin JWD, Seo YD, Gener-Ricos G, Keung EZ, Burton EM, Davies MA, McQuade JL, Lazar AJ, Mason R, Millward M, Sandhu S, Khoo C, Warburton L, Guerra V, Haydon A, Dearden H, Menzies AM, Carlino MS, Smith JL, Mollee P, Burgess M, Mapp S, Keane C, Atkinson V, Parikh SA, Markovic SN, Ding W, Call TG, Hampel PJ, Long GV, Wargo JA, Ferrajoli A. Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia. Ann Oncol. 2023 Sep; 34 (9):796-805 Epub 2023 July 04
    View PubMed
  33. Cass SH, Tobin JWD, Seo YD, Gener-Ricos G, Keung EZ, Burton EM, Davies MA, McQuade JL, Lazar AJ, Mason R, Millward M, Sandhu S, Khoo C, Warburton L, Guerra V, Haydon A, Dearden H, Menzies AM, Carlino MS, Smith JL, Mollee P, Burgess M, Mapp S, Keane C, Atkinson V, Parikh SA, Markovic SN, Ding W, Call TG, Hampel PJ, Long GV, Wargo JA, Ferrajoli A. Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia. Ann Oncol. 2023 Sep; 34 (9):796-805 Epub 2023 July 04
    View PubMed
  34. Griffin R, Wiedmeier-Nutor JE, Parikh SA, McCabe CE, O'Brien DR, Boddicker NJ, Kleinstern G, Rabe KG, Bruins L, Brown S, Bonolo de Campos C, Ding W, Leis JF, Hampel PJ, Call TG, Van Dyke DL, Kay NE, Cerhan JR, Yan H, Slager SL, Braggio E. Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL. Blood Adv. 2023 Jul 11; 7 (13):3169-3179
    View PubMed
  35. Griffin R, Wiedmeier-Nutor JE, Parikh SA, McCabe CE, O'Brien DR, Boddicker NJ, Kleinstern G, Rabe KG, Bruins L, Brown S, Bonolo de Campos C, Ding W, Leis JF, Hampel PJ, Call TG, Van Dyke DL, Kay NE, Cerhan JR, Yan H, Slager SL, Braggio E. Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL. Blood Adv. 2023 Jul 11; 7 (13):3169-3179
    View PubMed
  36. Hampel PJ, Parikh SA. Correction: Chronic lymphocytic leukemia treatment algorithm 2022. Blood Cancer J. 2022 Dec 22; 12 (12):172
    View PubMed
  37. Hampel PJ, Parikh SA. Correction: Chronic lymphocytic leukemia treatment algorithm 2022. Blood Cancer J. 2022 Dec 22; 12 (12):172
    View PubMed
  38. Hampel PJ, Parikh SA. Chronic lymphocytic leukemia treatment algorithm 2022. Blood Cancer J. 2022 Nov 29; 12 (11):161
    View PubMed
  39. Hampel PJ, Parikh SA. Chronic lymphocytic leukemia treatment algorithm 2022. Blood Cancer J. 2022 Nov 29; 12 (11):161
    View PubMed
  40. Hampel PJ, Rabe KG, Call TG, Ding W, Leis JF, Kenderian SS, Muchtar E, Wang Y, Koehler AB, Parrondo R, Schwager SM, Shi M, Braggio E, Slager SL, Kay NE, Parikh SA. Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia. Br J Haematol. 2022 Oct; 199 (2):239-244 Epub 2022 July 16
    View PubMed
  41. Hampel PJ, Rabe KG, Call TG, Ding W, Leis JF, Kenderian SS, Muchtar E, Wang Y, Koehler AB, Parrondo R, Schwager SM, Shi M, Braggio E, Slager SL, Kay NE, Parikh SA. Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia. Br J Haematol. 2022 Oct; 199 (2):239-244 Epub 2022 July 16
    View PubMed
  42. Hampel PJ, Rabe KG, Call TG, Ding W, Leis JF, Chanan-Khan AA, Kenderian SS, Muchtar E, Wang Y, Ailawadhi S, Koehler AB, Parrondo R, Schwager SM, Sher T, Hanson CA, Shi M, Van Dyke DL, Braggio E, Slager SL, Kay NE, Parikh SA. Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib. Blood Cancer J. 2022 Sep 1; 12 (9):124 Epub 2022 Sept 01
    View PubMed
  43. Hampel PJ, Rabe KG, Call TG, Ding W, Leis JF, Chanan-Khan AA, Kenderian SS, Muchtar E, Wang Y, Ailawadhi S, Koehler AB, Parrondo R, Schwager SM, Sher T, Hanson CA, Shi M, Van Dyke DL, Braggio E, Slager SL, Kay NE, Parikh SA. Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib. Blood Cancer J. 2022 Sep 1; 12 (9):124 Epub 2022 Sept 01
    View PubMed
  44. Kay NE, Hampel PJ, Van Dyke DL, Parikh SA. CLL update 2022: A continuing evolution in care. Blood Rev. 2022 Jul; 54:100930 Epub 2022 Jan 26
    View PubMed
  45. Kay NE, Hampel PJ, Van Dyke DL, Parikh SA. CLL update 2022: A continuing evolution in care. Blood Rev. 2022 Jul; 54:100930 Epub 2022 Jan 26
    View PubMed
  46. Salama Y, Zhao F, Oliveira JL, Yuan J, Jevremovic D, Go RS, Ding W, Parikh SA, Shah MV, Hampel PJ, Al-Kali A, Morice WG, Shi M. Isolated anemia in patients with large granular lymphocytic leukemia (LGLL). Blood Cancer J. 2022 Feb 22; 12 (2):30
    View PubMed
  47. Salama Y, Zhao F, Oliveira JL, Yuan J, Jevremovic D, Go RS, Ding W, Parikh SA, Shah MV, Hampel PJ, Al-Kali A, Morice WG, Shi M. Isolated anemia in patients with large granular lymphocytic leukemia (LGLL). Blood Cancer J. 2022 Feb 22; 12 (2):30
    View PubMed
  48. Muchtar E, Koehler AB, Johnson MJ, Rabe KG, Ding W, Call TG, Leis JF, Kenderian SS, Hayman SR, Wang Y, Hampel PJ, Holets MA, Darby HC, Slager SL, Kay NE, Miao C, Canniff J, Whitaker JA, Levin MJ, Schmid DS, Kennedy RB, Weinberg A, Parikh SA. Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. Am J Hematol. 2022 Jan 1; 97 (1):90-98 Epub 2021 Nov 05
    View PubMed
  49. Muchtar E, Koehler AB, Johnson MJ, Rabe KG, Ding W, Call TG, Leis JF, Kenderian SS, Hayman SR, Wang Y, Hampel PJ, Holets MA, Darby HC, Slager SL, Kay NE, Miao C, Canniff J, Whitaker JA, Levin MJ, Schmid DS, Kennedy RB, Weinberg A, Parikh SA. Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. Am J Hematol. 2022 Jan 1; 97 (1):90-98 Epub 2021 Nov 05
    View PubMed
  50. Abeykoon JP, Hampel PJ, King RL, Wood AJ, Larson MC, Nowakowski KE, Zanwar SS, Dasari S, Ruan GJ, Ravindran A, Wellik LE, Paludo J, Link BK, Cerhan JR, Ansell SM, Nowakowski GS, Thompson CA, Maurer MJ, Wenzl K, Novak AJ, Wu X, Habermann TM, Witzig TE. The significance of gradient expression of chromosome region maintenance protein 1 (exportin1) in large cell lymphoma. Haematologica. 2021 Aug 1; 106 (8):2261-2264 Epub 2021 Aug 01
    View PubMed
  51. Abeykoon JP, Hampel PJ, King RL, Wood AJ, Larson MC, Nowakowski KE, Zanwar SS, Dasari S, Ruan GJ, Ravindran A, Wellik LE, Paludo J, Link BK, Cerhan JR, Ansell SM, Nowakowski GS, Thompson CA, Maurer MJ, Wenzl K, Novak AJ, Wu X, Habermann TM, Witzig TE. The significance of gradient expression of chromosome region maintenance protein 1 (exportin1) in large cell lymphoma. Haematologica. 2021 Aug 1; 106 (8):2261-2264 Epub 2021 Aug 01
    View PubMed
  52. Audil HY, Hampel PJ, Van Dyke DL, Achenbach SJ, Rabe KG, Smoley SA, Call TG, Ding W, Shi M, Hanson CA, Wang Y, Muchtar E, Koehler AB, Schwager SM, Leis JF, Braggio E, Slager SL, Kay NE, Kenderian SS, Parikh SA. The prognostic significance of del6q23 in chronic lymphocytic leukemia. Am J Hematol 2021 Jun 1; 96 (6):E203-E206 Epub 2021 Apr 07
    View PubMed
  53. Hampel PJ, Parikh SA, Call TG. Incorporating molecular biomarkers into the continuum of care in chronic lymphocytic leukemia. Leuk Lymphoma. 2021 Jun; 62 (6):1289-1301 Epub 2021 Jan 07
    View PubMed
  54. Audil HY, Hampel PJ, Van Dyke DL, Achenbach SJ, Rabe KG, Smoley SA, Call TG, Ding W, Shi M, Hanson CA, Wang Y, Muchtar E, Koehler AB, Schwager SM, Leis JF, Braggio E, Slager SL, Kay NE, Kenderian SS, Parikh SA. The prognostic significance of del6q23 in chronic lymphocytic leukemia. Am J Hematol 2021 Jun 1; 96 (6):E203-E206 Epub 2021 Apr 07
    View PubMed
  55. Hampel PJ, Parikh SA, Call TG. Incorporating molecular biomarkers into the continuum of care in chronic lymphocytic leukemia. Leuk Lymphoma. 2021 Jun; 62 (6):1289-1301 Epub 2021 Jan 07
    View PubMed
  56. Tian S, Zhang H, Zhang P, Kalmbach M, Lee JH, Ordog T, Hampel PJ, Call TG, Witzig TE, Kay NE, Klee EW, Slager SL, Yan H, Ding W. Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemia. Sci Rep. 2021 Apr 15; 11 (1):8318
    View PubMed
  57. Tian S, Zhang H, Zhang P, Kalmbach M, Lee JH, Ordog T, Hampel PJ, Call TG, Witzig TE, Kay NE, Klee EW, Slager SL, Yan H, Ding W. Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemia. Sci Rep. 2021 Apr 15; 11 (1):8318
    View PubMed
  58. Hampel PJ, Parikh SA, Call TG, Shah MV, Bennani NN, Al-Kali A, Rabe KG, Wang Y, Muchtar E, Leis JF, Kenderian SS, Koehler AB, Schwager SM, Slager SL, Kay NE, Hanson CA, Van Dyke DL, Shi M, Ding W. Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. Blood Cancer J 2021 Mar 2; 11 (3):47 Epub 2021 Mar 02
    View PubMed
  59. Hampel PJ, Parikh SA, Call TG, Shah MV, Bennani NN, Al-Kali A, Rabe KG, Wang Y, Muchtar E, Leis JF, Kenderian SS, Koehler AB, Schwager SM, Slager SL, Kay NE, Hanson CA, Van Dyke DL, Shi M, Ding W. Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. Blood Cancer J 2021 Mar 2; 11 (3):47 Epub 2021 Mar 02
    View PubMed
  60. Hampel PJ, Call TG, Rabe KG, Ding W, Muchtar E, Kenderian SS, Wang Y, Leis JF, Witzig TE, Koehler AB, Fonder AL, Schwager SM, Van Dyke DL, Braggio E, Slager SL, Kay NE, Parikh SA. Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia. Oncologist. 2020 Nov; 25 (11):974-980 Epub 2020 Sept 20
    View PubMed
  61. Hampel PJ, Call TG, Rabe KG, Ding W, Muchtar E, Kenderian SS, Wang Y, Leis JF, Witzig TE, Koehler AB, Fonder AL, Schwager SM, Van Dyke DL, Braggio E, Slager SL, Kay NE, Parikh SA. Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia. Oncologist. 2020 Nov; 25 (11):974-980 Epub 2020 Sept 20
    View PubMed
  62. Koehler AB, Leung N, Call TG, Rabe KG, Achenbach SJ, Ding W, Kenderian SS, Leis JF, Wang Y, Muchtar E, Hayman SR, Hampel PJ, Finnes HD, Schwager SM, Slager SL, Kay NE, Parikh SA. Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice. Leuk Lymphoma. 2020 Oct; 61 (10):2383-2388 Epub 2020 May 25
    View PubMed
  63. Koehler AB, Leung N, Call TG, Rabe KG, Achenbach SJ, Ding W, Kenderian SS, Leis JF, Wang Y, Muchtar E, Hayman SR, Hampel PJ, Finnes HD, Schwager SM, Slager SL, Kay NE, Parikh SA. Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice. Leuk Lymphoma. 2020 Oct; 61 (10):2383-2388 Epub 2020 May 25
    View PubMed
  64. Hampel PJ, Cherng HJ, Call TG, Ding W, Khanlari M, McPhail ED, Miranda RN, Lin P, Tawbi HA, Ferrajoli A, Wierda WG, Jain N, Parikh SA. Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib. Blood Adv. 2020 Sep 22; 4 (18):4508-4511
    View PubMed
  65. Hampel PJ, Cherng HJ, Call TG, Ding W, Khanlari M, McPhail ED, Miranda RN, Lin P, Tawbi HA, Ferrajoli A, Wierda WG, Jain N, Parikh SA. Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib. Blood Adv. 2020 Sep 22; 4 (18):4508-4511
    View PubMed
  66. Hampel PJ, Call TG, Ding W, Muchtar E, Kenderian SS, Wang Y, Leis JF, Witzig TE, Koehler AB, Fonder AL, Schwager SM, Rabe KG, Van Dyke DL, Braggio E, Slager SL, Kay NE, Parikh SA. Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare. Am J Hematol 2020 Mar; 95 (3):E57-E60 Epub 2019 Dec 13
    View PubMed
  67. Hampel PJ, Call TG, Ding W, Muchtar E, Kenderian SS, Wang Y, Leis JF, Witzig TE, Koehler AB, Fonder AL, Schwager SM, Rabe KG, Van Dyke DL, Braggio E, Slager SL, Kay NE, Parikh SA. Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare. Am J Hematol 2020 Mar; 95 (3):E57-E60 Epub 2019 Dec 13
    View PubMed
  68. Hampel PJ, Ding W, Call TG, Rabe KG, Kenderian SS, Witzig TE, Muchtar E, Leis JF, Chanan-Khan AA, Koehler AB, Fonder AL, Schwager SM, Slager SL, Shanafelt TD, Kay NE, Parikh SA. Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. Leuk Lymphoma. 2019 Nov; 60 (11):2712-2719 Epub 2019 Apr 24
    View PubMed
  69. Hampel PJ, Ding W, Call TG, Rabe KG, Kenderian SS, Witzig TE, Muchtar E, Leis JF, Chanan-Khan AA, Koehler AB, Fonder AL, Schwager SM, Slager SL, Shanafelt TD, Kay NE, Parikh SA. Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. Leuk Lymphoma. 2019 Nov; 60 (11):2712-2719 Epub 2019 Apr 24
    View PubMed
  70. Hampel PJ, Larson MC, Kabat B, Call TG, Ding W, Kenderian SS, Bowen D, Boysen J, Schwager SM, Leis JF, Chanan-Khan AA, Muchtar E, Hanson CA, Slager SL, Kay NE, Chaffee KG, Shanafelt TD, Parikh SA. Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre. Br J Haematol. 2018 Nov; 183 (3):421-427 Epub 2018 Aug 16
    View PubMed
  71. Hampel PJ, Larson MC, Kabat B, Call TG, Ding W, Kenderian SS, Bowen D, Boysen J, Schwager SM, Leis JF, Chanan-Khan AA, Muchtar E, Hanson CA, Slager SL, Kay NE, Chaffee KG, Shanafelt TD, Parikh SA. Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre. Br J Haematol. 2018 Nov; 183 (3):421-427 Epub 2018 Aug 16
    View PubMed
  72. Ramos GP, Binder M, Hampel P, Braga Neto MB, Sunjaya D, Al Bawardy B, Abu Dayyeh BK, Buttar NS, Bruining DH, Coelho-Prabhu N, Prabhu-Coelho N, Larson MV, Wong Kee Song LM, Rajan E. Outcomes of endoscopic intervention for overt GI bleeding in severe thrombocytopenia. Gastrointest Endosc. 2018 Jul; 88 (1):55-61 Epub 2018 Feb 02
    View PubMed
  73. Ramos GP, Binder M, Hampel P, Braga Neto MB, Sunjaya D, Al Bawardy B, Abu Dayyeh BK, Buttar NS, Bruining DH, Coelho-Prabhu N, Prabhu-Coelho N, Larson MV, Wong Kee Song LM, Rajan E. Outcomes of endoscopic intervention for overt GI bleeding in severe thrombocytopenia. Gastrointest Endosc. 2018 Jul; 88 (1):55-61 Epub 2018 Feb 02
    View PubMed
  74. Parikh SA, Chaffee KG, Larson MC, Hampel PJ, Call TG, Ding W, Kenderian SS, Leis JF, Chanan-Khan AA, Conte MJ, Bowen D, Schwager SM, Slager SL, Hanson CA, Kay NE, Shanafelt TD. Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis. Haematologica 2018 Jun; 103 (6):e237-e240 Epub 2018 Feb 01
    View PubMed
  75. Parikh SA, Chaffee KG, Larson MC, Hampel PJ, Call TG, Ding W, Kenderian SS, Leis JF, Chanan-Khan AA, Conte MJ, Bowen D, Schwager SM, Slager SL, Hanson CA, Kay NE, Shanafelt TD. Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis. Haematologica 2018 Jun; 103 (6):e237-e240 Epub 2018 Feb 01
    View PubMed
  76. Hampel PJ, Chaffee KG, King RL, Simonetto D, Larson MC, Achenbach S, Call TG, Ding W, Kenderian SS, Leis JF, Chanan-Khan AA, Bowen DA, Conte MJ, Schwager SM, Hanson CA, Slager SL, Kay NE, Shanafelt TD, Parikh SA. Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings. Am J Hematol. 2017 Dec; 92 (12):1362-1369 Epub 2017 Oct 19
    View PubMed
  77. Hampel PJ, Chaffee KG, King RL, Simonetto D, Larson MC, Achenbach S, Call TG, Ding W, Kenderian SS, Leis JF, Chanan-Khan AA, Bowen DA, Conte MJ, Schwager SM, Hanson CA, Slager SL, Kay NE, Shanafelt TD, Parikh SA. Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings. Am J Hematol. 2017 Dec; 92 (12):1362-1369 Epub 2017 Oct 19
    View PubMed
  78. Hampel PJ, Chela H, Irish J, Parker R. Isolated Intestinal Angioedema Induced by an ACE-inhibitor Journal of Academic Hospital Medicine. 2015; 7(3).
  79. Hampel PJ, Chela H, Irish J, Parker R. Isolated Intestinal Angioedema Induced by an ACE-inhibitor Journal of Academic Hospital Medicine. 2015; 7(3).
  80. Hong Z, Ersoy I, Sun M, Bunyak F, Hampel P, Hong Z, Sun Z, Li Z, Levitan I, Meininger GA, Palaniappan K. Influence of membrane cholesterol and substrate elasticity on endothelial cell spreading behavior. J Biomed Mater Res A. 2013 Jul; 101 (7):1994-2004 Epub 2012 Dec 13
    View PubMed
  81. Hong Z, Ersoy I, Sun M, Bunyak F, Hampel P, Hong Z, Sun Z, Li Z, Levitan I, Meininger GA, Palaniappan K. Influence of membrane cholesterol and substrate elasticity on endothelial cell spreading behavior. J Biomed Mater Res A. 2013 Jul; 101 (7):1994-2004 Epub 2012 Dec 13
    View PubMed
  82. Hong Z, Staiculescu MC, Hampel P, Levitan I, Forgacs G. How cholesterol regulates endothelial biomechanics. Front Physiol. 2012; 3:426 Epub 2012 Nov 15
    View PubMed
  83. Hong Z, Staiculescu MC, Hampel P, Levitan I, Forgacs G. How cholesterol regulates endothelial biomechanics. Front Physiol. 2012; 3:426 Epub 2012 Nov 15
    View PubMed
  84. Hong Z, Luz GM, Hampel PJ, Jin M, Liu A, Chen X, Mano JF. Mono-dispersed bioactive glass nanospheres: preparation and effects on biomechanics of mammalian cells. J Biomed Mater Res A. 2010 Dec 1; 95 (3):747-54
    View PubMed
  85. Hong Z, Luz GM, Hampel PJ, Jin M, Liu A, Chen X, Mano JF. Mono-dispersed bioactive glass nanospheres: preparation and effects on biomechanics of mammalian cells. J Biomed Mater Res A. 2010 Dec 1; 95 (3):747-54
    View PubMed